Skip to main content

Advertisement

SpringerLink
Log in

Medical treatment of cervical intraepithelial neoplasia II, III: an update review

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Cervical intraepithelial neoplasia (CIN) II, III is a preinvasive stage of squamous cell carcinoma of the uterine cervix. The standard treatment for CIN II, III consists of ablation and excision. However, nonsurgical treatment may be necessary for some women to preserve future reproductive potential. This review was conducted to summarize available published data on the efficacy and safety of medical treatment for CIN II, III. Based on existing studies, cyclooxygenase (COX)-2 inhibitors; indole-3-carbinol; and novel immunotherapy agents, including ZYC101a, MVA E2, and HspE7, have been observed as possessing therapeutic activity without any major treatment-related complications. These promising results provide important data for the future direction of clinical research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Walboomers JM, Jacobs MV, Manos MM, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19

    Article  PubMed  CAS  Google Scholar 

  2. Munoz N, Bosch FX, de Sanjose S, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527

    Article  PubMed  Google Scholar 

  3. Ostor AG (1993) Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12:186–192

    Article  PubMed  CAS  Google Scholar 

  4. Mitchell MF, Hittelman WN, Hong WK, et al. (1994) The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev 3:619–626

    PubMed  CAS  Google Scholar 

  5. Wright TC, Jr., Massad LS, Dunton CJ, et al. (2007) 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 197:340–345

    Article  PubMed  Google Scholar 

  6. Moscicki AB, Schiffman M, Kjaer S, et al. (2006) Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 24(Suppl 3):S42–S51

    Article  Google Scholar 

  7. Kietpeerakool C, Srisomboon J, Suprasert P, et al. (2007) Routine prophylactic application of Monsel’s solution after loop electrosurgical excision procedure of the cervix: is it necessary? J Obstet Gynaecol Res 33:299–304

    Article  PubMed  Google Scholar 

  8. Hillard PA, Biro FM, Wildey L (1991) Complications of cervical cryotherapy in adolescents. J Reprod Med 36:711–716

    PubMed  CAS  Google Scholar 

  9. Jakobsson M, Gissler M, Sainio S, et al. (2007) Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol 109:309–313

    PubMed  Google Scholar 

  10. Bell MC, Crowley-Nowick P, Bradlow HL, et al. (2000) Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 78:123–129

    Article  PubMed  CAS  Google Scholar 

  11. Dai Y, Zhang X, Peng Y, et al. (2005) The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma. Gynecol Oncol 97:96–103

    Article  PubMed  CAS  Google Scholar 

  12. Dursun P, Yuce K, Usubutun A, et al. (2007) Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables. Int J Gynecol Cancer 17:164–173

    Article  PubMed  CAS  Google Scholar 

  13. Lee JS, Choi YD, Lee JH, et al. (2004) Expression of cyclooxygenase-2 in adenocarcinomas of the uterine cervix and its relation to angiogenesis and tumor growth. Gynecol Oncol 95: 523–529

    Article  PubMed  CAS  Google Scholar 

  14. Reddy BS, Hirose Y, Lubet R, et al. (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60:293–297

    PubMed  CAS  Google Scholar 

  15. Hawk E, Lubet R, Limburg P (1999) Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86:2551–2563

    Article  PubMed  CAS  Google Scholar 

  16. Farley JH, Truong V, Goo E, et al. (2006) A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor celecoxib in the treatment of cervical dysplasia. Gynecol Oncol 103:425–430

    Article  PubMed  CAS  Google Scholar 

  17. Hefler LA, Grimm C, Speiser P, et al. (2006) The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial. Eur J Obstet Gynecol Reprod Biol 125:251–254

    Article  PubMed  CAS  Google Scholar 

  18. Solomon SD, McMurray JJ, Pfeffer MA, et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080

    Article  PubMed  CAS  Google Scholar 

  19. Bresalier RS, Sandler RS, Quan H, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102

    Article  PubMed  CAS  Google Scholar 

  20. Boiko IV, Mitchell MF, Hu W, et al. (1998) Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial. Clin Cancer Res 4:1383–1391

    PubMed  CAS  Google Scholar 

  21. Gerner EW, Meyskens FL Jr (2004) Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4:781–792

    Article  PubMed  CAS  Google Scholar 

  22. Seiler N, Raul F (2005) Polyamines and apoptosis. J Cell Mol Med 9:623–642

    Article  PubMed  CAS  Google Scholar 

  23. Mitchell MF, Tortolero-Luna G, Lee JJ, et al. (1998) Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 4:303–310

    PubMed  CAS  Google Scholar 

  24. Vlastos AT, West LA, Atkinson EN, et al. (2005) Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin Cancer Res 11:390–396

    PubMed  CAS  Google Scholar 

  25. Meyskens FL Jr, Gilmartin E, Alberts DS, et al. (1982) Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep 66:1315–1319

    PubMed  Google Scholar 

  26. Meyskens FL Jr, Graham V, Chvapil M, et al. (1983) A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J Natl Cancer Inst 71:921–925

    PubMed  Google Scholar 

  27. Surwit EA, Graham V, Droegemueller W, et al. (1982) Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol 143:821–823

    PubMed  CAS  Google Scholar 

  28. Weiner SA, Surwit EA, Graham VE, et al. (1986) A phase I trial of topically applied trans-retinoic acid in cervical dysplasia — clinical efficacy. Invest New Drugs 4:241–244

    Article  PubMed  CAS  Google Scholar 

  29. Meyskens FL Jr, Surwit E, Moon TE, et al. (1994) Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 86:539–543

    Article  PubMed  Google Scholar 

  30. Follen M, Atkinson EN, Schottenfeld D, et al. (2001) A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 7:3356–3365

    PubMed  CAS  Google Scholar 

  31. Alvarez RD, Conner MG, Weiss H, et al. (2003) The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol Biomarkers Prev 12:114–119

    PubMed  CAS  Google Scholar 

  32. Ruffin MT, Bailey JM, Normolle DP, et al. (2004) Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol Biomarkers Prev 13: 2148–2152

    PubMed  CAS  Google Scholar 

  33. Helm CW, Lorenz DJ, Meyer NJ, et al. (2007) Retinoids for preventing the progression of cervical intra-epithelial neoplasia. Cochrane Database Syst Rev 4:CD003296

    Google Scholar 

  34. Kwasniewska A, Tukendorf A, Semczuk M (2997) Folate deficiency and cervical intraepithelial neoplasia. Eur J Gynaecol Oncol 18:526–530

    Google Scholar 

  35. Piyathilake CJ, Henao OL, Macaluso M, et al. (2004) Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res 64:8788–8793

    Article  PubMed  CAS  Google Scholar 

  36. Sedjo RL, Inserra P, Abrahamsen M, et al. (2002) Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women. Cancer Epidemiol Biomarkers Prev 11:353–359

    PubMed  CAS  Google Scholar 

  37. Piyathilake CJ, Macaluso M, Brill I, et al. (2007) Lower red blood cell folate enhances the HPV-16-associated risk of cervical intraepithelial neoplasia. Nutrition 23:203–210

    Article  PubMed  CAS  Google Scholar 

  38. Butterworth CE Jr, Hatch KD, Soong SJ, et al. (1992) Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol 166:803–809

    PubMed  Google Scholar 

  39. Childers JM, Chu J, Voigt LF, et al. (1995) Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 4:155–159

    PubMed  CAS  Google Scholar 

  40. Palan PR, Mikhail MS, Basu J, et al. (1992) Beta-carotene levels in exfoliated cervicovaginal epithelial cells in cervical intraepithelial neoplasia and cervical cancer. Am J Obstet Gynecol 167: 1899–1903

    PubMed  CAS  Google Scholar 

  41. Manetta A, Schubbert T, Chapman J, et al. (1996) Beta-carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Prev 5:929–932

    PubMed  CAS  Google Scholar 

  42. Romney SL, Ho GY, Palan PR, et al. (1997) Effects of betacarotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 65:483–492

    Article  PubMed  CAS  Google Scholar 

  43. Keefe KA, Schell MJ, Brewer C, et al. (2001) A randomized, double blind, phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 10:1029–1035

    PubMed  CAS  Google Scholar 

  44. Bradlow HL, Michnovicz J, Telang NT, et al. (1991) Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12:1571–1574

    Article  PubMed  CAS  Google Scholar 

  45. van Poppel G, Verhoeven DT, Verhagen H, et al. (1999) Brassica vegetables and cancer prevention. Epidemiology and mechanisms. Adv Exp Med Biol 472:159–168

    PubMed  Google Scholar 

  46. Garikapaty VP, Ashok BT, Chen YG, et al. (2005) Anticarcinogenic and anti-metastatic properties of indole-3-carbinol in prostate cancer. Oncol Rep 13:89–93

    PubMed  CAS  Google Scholar 

  47. Garikapaty VP, Ashok BT, Tadi K, et al. (2006) 3,3′-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun 340:718–725

    Article  PubMed  CAS  Google Scholar 

  48. Qi M, Anderson AE, Chen DZ, et al. (2005) Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Mol Med 11:59–63

    Article  PubMed  CAS  Google Scholar 

  49. Auborn KJ, Fan S, Rosen EM, et al. (2003) Indole-3-carbinol is a negative regulator of estrogen. J Nutr 133:2470S–2475S.

    PubMed  CAS  Google Scholar 

  50. Klencke B, Matijevic M, Urban RG, et al. (2002) Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 8:1028–1037

    PubMed  CAS  Google Scholar 

  51. Sheets EE, Urban RG, Crum CP, et al. (2003) Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188:916–926

    Article  PubMed  CAS  Google Scholar 

  52. Garcia F, Petry KU, Muderspach L, et al. (2004) ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 103:317–326

    PubMed  CAS  Google Scholar 

  53. Rosales C, Graham VV, Rosas GA, et al. (2000) A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother 49:347–360

    Article  PubMed  CAS  Google Scholar 

  54. Corona Gutierrez CM, Tinoco A, Lopez Contreras M, et al. (2002) Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther 13:1127–1140

    Article  PubMed  Google Scholar 

  55. Corona Gutierrez CM, Tinoco A, Navarro T, et al. (2004) Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 15:421–431

    Article  PubMed  CAS  Google Scholar 

  56. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. (2006) Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13:592–597

    Article  PubMed  CAS  Google Scholar 

  57. Zugel U, Kaufmann SH (1999) Immune response against heat shock proteins in infectious diseases. Immunobiology 201:22–35

    PubMed  CAS  Google Scholar 

  58. Goldstone SE, Palefsky JM, Winnett MT, et al. (2002) Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 45:502–507

    Article  PubMed  Google Scholar 

  59. Derkay CS, Smith RJ, McClay J, et al. (2005) HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol 114:730–737

    PubMed  Google Scholar 

  60. Einstein MH, Kadish AS, Burk RD, et al. (2007) Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 106:453–460

    Article  PubMed  CAS  Google Scholar 

  61. Roman LD, Wilczynski S, Muderspach LI, et al. (2007) A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 106:558–566

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand

    Chumnan Kietpeerakool & Jatupol Srisomboon

Authors
  1. Chumnan Kietpeerakool
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jatupol Srisomboon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chumnan Kietpeerakool.

About this article

Cite this article

Kietpeerakool, C., Srisomboon, J. Medical treatment of cervical intraepithelial neoplasia II, III: an update review. Int J Clin Oncol 14, 37–42 (2009). https://doi.org/10.1007/s10147-008-0795-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-008-0795-x

Key words

Search

Navigation